Unknown

Dataset Information

Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.


ABSTRACT:

Background

Based on results of the Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension (AMBITION) trial, upfront combination therapy is recommended for treatment-naive patients with low-risk pulmonary arterial hypertension (PAH). However, conflicting data exist whether adopting this treatment strategy in this risk group is beneficial or well tolerated.

Research question

Do patients with low-risk PAH really benefit from upfront combination therapy?

Study design and methods

Using the data from the original AMBITION trial, patients with PAH were classified as low, intermediate, or high risk using the Registry to Evaluate Early and Long-term PAH Disease Management 2.0 (REVEAL 2.0) score and the Pulmonary Hypertension Outcomes and Risk Assessment (PH

SUBMITTER: Fauvel C 

PROVIDER: S-EPMC10716797 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature